LLY

981.44

-2.25%↓

JNJ

229.27

+1.11%↑

ABBV

208.64

-0.85%↓

UNH

390.17

-0.89%↓

AZN

184.08

+1.35%↑

LLY

981.44

-2.25%↓

JNJ

229.27

+1.11%↑

ABBV

208.64

-0.85%↓

UNH

390.17

-0.89%↓

AZN

184.08

+1.35%↑

LLY

981.44

-2.25%↓

JNJ

229.27

+1.11%↑

ABBV

208.64

-0.85%↓

UNH

390.17

-0.89%↓

AZN

184.08

+1.35%↑

LLY

981.44

-2.25%↓

JNJ

229.27

+1.11%↑

ABBV

208.64

-0.85%↓

UNH

390.17

-0.89%↓

AZN

184.08

+1.35%↑

LLY

981.44

-2.25%↓

JNJ

229.27

+1.11%↑

ABBV

208.64

-0.85%↓

UNH

390.17

-0.89%↓

AZN

184.08

+1.35%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Отворен

1.18 3.51

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.1400000000000001

Максимум

1.23

Ключови измерители
By Trading Economics
Приходи	3.5M -20M
EPS	-0.32
Служители	49
EBITDA	6.6M -22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+132.17% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-6.8M 74M
Предишно отваряне	-2.33
Предишно затваряне	1.18

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.05.2026 г., 23:53 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17.05.2026 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

UOB: Transactions Part of Group's Capital Reallocation Strategy

17.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

UOB: Share Sale Agreements Entered With Singland Properties

17.05.2026 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Fund Stake Acquisition via Internal Resources

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire Stake for $389 Million

17.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16.05.2026 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16.05.2026 г., 15:26 ч. UTC

Придобивния, сливания и поглъщания

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

132.17% нагоре

12-месечна прогноза

Среден 2.67 USD 132.17%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.